More importantly, we demonstrate that AMPK activation prevents both cardiomyocyte hypertrophy in vitro and cardiac hypertrophy in vivo by inhibiting O-GlcNAc signaling via its actions on GFAT and OGT. The gene discussed is PRKAA2; the disease is cardiac hypertrophy.